Estados Unidos · Plataformas y datos · MarketBeat

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Publicado por MarketBeat · Estados Unidos hace 2 h

Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

También te puede interesar

Is It Too Late to Buy Energy Transfer After a 25% Rally? History Has a Clear Answer.

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Ethereum Price Prediction: ETH Dipped Below $2,300 This Week. Where Is the Next Floor?

TeraWulf CEO Paul Prager Turns Elon Musk’s ‘Stranded Compute’ Warning Into A Buying Pitch

Vanguard flags a hidden AI risk in your value fund

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Compartir

También te puede interesar

Is It Too Late to Buy Energy Transfer After a 25% Rally? History Has a Clear Answer.

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Ethereum Price Prediction: ETH Dipped Below $2,300 This Week. Where Is the Next Floor?

TeraWulf CEO Paul Prager Turns Elon Musk’s ‘Stranded Compute’ Warning Into A Buying Pitch

Vanguard flags a hidden AI risk in your value fund